Novo to pay nearly $60M to settle Victoza marketing suits with DOJ, whistleblowers. Exposing Misconduct.

Novo to pay nearly $60M to settle Victoza marketing suits with DOJ, whistleblowers

September 6, 2017

Novo Nordisk just won a nod from the FDA for the cardiovascular risk reduction of Victoza, which should further propel sales of the blockbuster. But in its own nod to a darker side of its sales history, the company has settled, for nearly $60 million, another batch of lawsuits over past marketing of the Type 2 diabetes drug.

The complaints from the Justice Department and sales reps-turned-whistleblowers alleged that Novo had flouted its Risk Evaluation and Mitigation Strategy (REMS) requirements. It was supposed to warn prescribers that Victoza had been associated with a risk of the rare cancer Medullary Thyroid Carcinoma, but the DOJ complaint says Novo had its sales team give doctors the impression that the REMS requirements “were erroneous, irrelevant, or unimportant.”

Under the $58.65 million settlement, Novo is giving up $12.15 million in profits and paying $46.5 million for alleged violations of the False Claims Act.

Read more here.
The materials on this website are for general information purposes only and should not be construed as legal advice, legal opinion or any other advice on any specific facts or circumstances. Readers should not act or refrain from acting upon this information without seeking professional advice. Transmission of information on or by use of this website is not intended to create, and receipt does not constitute, a lawyer-client relationship between the sender and receiver.
Mobile Menu